| Literature DB >> 34676374 |
Alexander H Pearlman1,2,3, Michael S Hwang1,2,3,4, Maximilian F Konig1,2,3,5, Emily Han-Chung Hsiue1,2,3, Jacqueline Douglass1,2,3, Sarah R DiNapoli1,2,3, Brian J Mog1,2,3,6, Chetan Bettegowda1,2,7,8, Drew M Pardoll8,9, Sandra B Gabelli8,10,11, Nicholas Papadopoulos1,2,9,12,13, Kenneth W Kinzler1,2,8,9,13, Bert Vogelstein1,2,3,8,9,12,13, Shibin Zhou14,15,16,17.
Abstract
Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients' tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34676374 PMCID： PMC8525885 DOI： 10.1038/s43018-021-00210-y
Source DB: PubMed Journal: Nat Cancer ISSN： 2662-1347